• 会议通知
  • 会议日程
  • 会议嘉宾
  • 会议门票
  • 参会报名

首页>商务会议>医疗医学> PEGS China 2016 第三届中国蛋白与抗体工程及研发峰会

PEGS China 2016 第三届中国蛋白与抗体工程及研发峰会

PEGS China 2016 第三届中国蛋白与抗体工程及研发峰会

时间:2016-04-05 08:00:00 至 2016-04-07 18:00:00结束
地点:上海 上海金茂君悦大酒店 浦东新区世纪大道88号

发布时间:2015-11-30 16:50:05

APP下载
邀请函下载 官方授权

推荐参加: 2017 中国国际生物医用材料产业博览会 (时间:2017-09-22 地点:上海 )

会议报名

门票名称单价(¥)截止时间数量
基础套餐 费用说明 包括一个会议或者SEMINAR4770.002016-01-15
标准套餐 费用说明 包括两个会议和SEMINAR 6360.002016-01-15

会议通知
Meeting notice

第三届“PEGS China:蛋白与抗体工程与研发峰会”将于2016年代表4月5日至7日再次在上海召开。

经过一年的精心筹备和策划,此次峰会将提供更广泛的主题,更深切的探讨,并标榜多名来自中美欧等国的领英科学家。200多名行业领导者将聚集于此,在历时三天的峰会上分享案例研究、未发表的数据、开展的讨论、以及关于中国生物医药行业的发展趋势和未来的观点。

2016年会议日程包括:
•Protein&Antibody Engineering 蛋白与抗体研发工程会议   
将汇聚顶尖研究人员,分享他们对蛋白与抗体分子设计和优化的见解,讨论他们在克服挑战的过程中采用的前沿技术和创新方法。

•Analytical Characterization of Biotherapeutics 生物药物特性分析会议    
将展现生物结构与功能评估的尖端工具、技术和方法,确定物理化学性质以及分析新型生物制剂和生物仿制药的高阶结构。

•Next-Generation Cancer Biotherapeutics 新一代肿瘤生物治疗会议   
将呈现开发下一代生物偶联技术、双特性和多特性抗体的临床更新的战略、展示性能更强的新型工程抗体,以提升疗效和抗肿瘤活性,此外还将提出发展免疫疗法抗体过程中克服挑战的方案。

•Protein Aggregates &Stability 蛋白质聚集和稳定性会议    
将邀请科学家们讨论聚集机制、预测聚集倾向、进行稳定性研究并比较蛋白质聚集体和粒子的界定工具和量化工具。

•Symposium on Clinical and Regulatory Strategies for Domestic and Global IND and BLA Filing 生物制品临床与监管战略座谈会  
聚焦于中国与全球新药研究(IND)和生物制品许可申请(BLA)的机会和方法。座谈会将针对现今适用于国际开发新产品的评估战略方式进行深切探讨。

【参会对象】

生物医药公司的研发人员/ 研发助理/研发总监/ 科学家/ 项目总监/VP

会议名称:PEGS China 2016 第三届中国蛋白与抗体工程及研发峰会

会议时间:2016年04月5-7 日

举办地点:上海.金茂君悦大酒店

会议日程
Meeting schedule

会议日程:

•Protein&Antibody Engineering 蛋白与抗体研发工程会议   
将汇聚顶尖研究人员,分享他们对蛋白与抗体分子设计和优化的见解,讨论他们在克服挑战的过程中采用的前沿技术和创新方法。

•Analytical Characterization of Biotherapeutics 生物药物特性分析会议    
将展现生物结构与功能评估的尖端工具、技术和方法,确定物理化学性质以及分析新型生物制剂和生物仿制药的高阶结构。

•Next-Generation Cancer Biotherapeutics 新一代肿瘤生物治疗会议   
将呈现开发下一代生物偶联技术、双特性和多特性抗体的临床更新的战略、展示性能更强的新型工程抗体,以提升疗效和抗肿瘤活性,此外还将提出发展免疫疗法抗体过程中克服挑战的方案。

•Protein Aggregates &Stability 蛋白质聚集和稳定性会议    
将邀请科学家们讨论聚集机制、预测聚集倾向、进行稳定性研究并比较蛋白质聚集体和粒子的界定工具和量化工具。

•Symposium on Clinical and Regulatory Strategies for Domestic and Global IND and BLA Filing 生物制品临床与监管战略座谈会  
聚焦于中国与全球新药研究(IND)和生物制品许可申请(BLA)的机会和方法。座谈会将针对现今适用于国际开发新产品的评估战略方式进行深切探讨。

注:详细日程请下载(右边干货分享位置)PDF文档《PEGS2016蛋白抗体研发峰会中文会议日程》

会议嘉宾
Meeting guest

PEGS China 2016 第三届中国蛋白与抗体工程及研发峰会

Weikang Tao
Jiangsu Henrui Medicine Co., Ltd. Ph.D., Vice President & CEO, R&D Center
演讲主题:Cancer Immunotherapy: Delivering the Promise——癌症免疫疗法:承诺的实现

Recent breakthroughs in treating different types of advanced-stage malignancies by harnessing self immunity against neoplastic cells showed a great promise of immunotherapy for cancer treatment. Various strategies have been employed to unleash, enhance or elicit anticancer immune reactions, which include T-cell checkpoint blockade, engineered T cells, BiTE, modified cytokines and cancer vaccines. This presentation will review recent progress in cancer immunotherapy and discuss some immunotherapeutic agents discovered and developed at HengRui Medicine Co., Ltd.

 PEGS China 2016 第三届中国蛋白与抗体工程及研发峰会
Daotian Fu
Livzon MabPharm Ph.D., General Manager

演讲主题:Update on Recent Regulatory Changes for Biologics Development in China——中国生物制剂研发的最新监管变

Over the past several years, the biotech industry in China has experienced tremendous growth, both in biosimilars and innovative biologics. In the meantime, the CFDA is also going through significant reforms with respect to guidance and the reviewing process for development of both biosimilars as well as innovative biologics. In this presentation, the author intends to provide an update on the recent development in CFDA’s guidance for biologics development in China, and how the biotech industry can best position itself to take advantage of the recent regulatory changes.

PEGS China 2016 第三届中国蛋白与抗体工程及研发峰会 
Herren Wu
MedImmune/AstraZeneca Ph.D., CTO
演讲主题:Engineering the Next-Generation Antibody-Drug Conjugates for Cancer Therapy——用于癌症治疗的新一代抗体偶联药物

Linking of highly potent cytotoxic warheads to tumor-targeting antibodies has the potential to attack tumors with missile-like precision and avoid toxicity to normal tissues. However, clinical observations indicate that the therapeutic window of most antibody-drug conjugates (ADCs) remains narrow. I will discuss our efforts in developing next-generation ADC technology which seeks to address the short-comings observed with current ADCs and help realize the full potential of this drug class to provide new breakthrough agents for the treatment of cancer.

 PEGS China 2016 第三届中国蛋白与抗体工程及研发峰会
Andrew Bradbury
Biosciences Division, Los Alamos National Laboratory MBBS, Ph.D., Research Scientist and Group Leader
演讲主题: AT THE CROSSROADS:GETTING TO REPRODUCIBLE RESEARCH ANTIBODIES——站在十字路口:如何获得可重复研究的抗体

Researchers all over the world routinely use antibodies, a critical class of commercially supplied reagents that are frequently unreliable. This situation affects reproducibility in biomedical research, wastes millions of dollars annually, and may affect clinical trials. This talk will provide an overview of the problem, argue that the time has come to express antibodies recombinantly and refer to them by their sequences, and provide possible ways to get to this ideal.

 PEGS China 2016 第三届中国蛋白与抗体工程及研发峰会
Paul W.H.I. Parren
Senior Vice President & Scientific Director, Genmab Ph.D.,
演讲主题:Developing Antibody-Drug Conjugates for the Treatment of Solid Cancers——抗体偶联药物治疗实体肿瘤的进展

Therapeutic antibodies have revolutionized the treatment of cancer. However, many patients still fail to respond or become resistant to targeted treatment and novel innovative approaches to improve therapy are therefore required. Chemical engineering of antibodies, fueled by recent molecular insights, is providing important opportunities for the development of more potent antibody therapeutics. The progress in two antibodydrug conjugate programs from Genmab’s portfolio will be highlighted.

 PEGS China 2016 第三届中国蛋白与抗体工程及研发峰会
Alain Beck
Antibody and ADC Physico-Chemistry, Centre d’Immunologie Pierre Fabre, France Ph.D., Senior Director,
演讲主题:KEYNOTE PRESENTATION: CUTTING-EDGE MASS SPECTROMETRY METHODS FOR ANTIBODY,BIOSIMILAR, BISPECIFIC AND ANTIBODY-DRUG CONJUGATES STRUCTURAL ASSESSMENT——抗体的尖端质谱法,双特异性生物仿制和抗体药物共轭结构的评估

A plethora of new mass spectrometry (MS) methods are used for antibody structural characterization and for biosimilarity assessment. In addition, these techniques are used to design and optimize more sophisticated and potent antibody derivatives such as ADCs (OptimADCs), bi- and multispecific antibodies, and controlled mixture of antibodies. Case studies based on state-of-the art MS methods such as Native and Ion-Mobility MS, Top-Down Sequencing, Proteomics and Sheathless Capillary Electrophoresis−Tandem MS will be presented and discussed.

 PEGS China 2016 第三届中国蛋白与抗体工程及研发峰会
Peter M.Tessier
Rensselaer Polytechnic Institute Ph.D., Richard Baruch M.D. Career Development Asso
演讲主题:Improved Methods for Designing and Evolving Antibodies——抗体设计和进化的改良方法

The biotech industry has seen an explosion in the development of therapeutic antibodies in the last decade. The advantages of antibodies are
compelling. Nevertheless, there are many challenges associated with antibody selection and engineering that require key technical advances to
simplify the rapid and reliable generation of potent antibody therapeutics. I will discuss.

 PEGS China 2016 第三届中国蛋白与抗体工程及研发峰会
Roland Kontermann
Institute of Cell Biology and Immunology, University of Stuttgart Ph.D., Professor, Biomedical Engineering
演讲主题:Engineering Principles to Generate Multivalent Antibody-TRAIL Fusion Proteins——多价抗体-TRAIL融合蛋白的制造工程原则

Fusion of TRAIL to antibody fragments has been shown to allow for a targeted delivery and the selective induction of tumor cell death.
We have engineered optimized single-chain derivatives of TRAIL (scTRAIL), which were employed to develop novel multivalent antibody-scTRAIL
fusion proteins with improved properties. These multivalent fusion proteins were generated employing either scFv-driven homodimerization or
various separate homodimerization modules. Targeting and controlled dimerization of scTRAIL fusion proteins provides a strategy to enforce
apoptosis induction, together with retained tumor selectivity and good in vivo tolerance.

 PEGS China 2016 第三届中国蛋白与抗体工程及研发峰会
Salvador Ventura
Biochemistry and Molecular Biology, Institute of Biotechnology and Biomedicine, University of Barcelona Ph.D., Professor
演讲主题:DESIGNING PROTEIN SOLUBILITY——设计蛋

One of the major challenges that one should face during the development of protein-based biopharmaceuticals is their inherent propensity to aggregate. Indeed, protein therapeutic agents are both stored and typically administered at very high concentrations. Under these conditions they can easily aggregate, impacting the product’s developability, stability, formulation, and immunogenicity. I will discuss how computationally-assisted design of protein structures solubility is helping us to overcome these limitations.

会议门票
Meeting ticket

PEGS China 2016

标准套餐  (包括两个会议和SEMINAR)                                           
Early Registration Rates until January 15                                6360.00
Advance Registration Rates until February 26                         6890.00
Standard Registration Rates after February 26 and onsite       7420.00

 

基础套餐  (包括一个会议或者SEMINAR )                                       
Early Registration Rates until January 15                                4770.00
Advance Registration Rates until February 26                        5300.00
Standard Registration Rates after February 26 and onsite      5830.00

*以上价格均为含税价, 提供正式发票.


标签: 肿瘤 抗体 疫苗 生物治疗

用户留言 还可以输入120个字


CheckCode

全部留言(0)


扫一扫立即购票

扫一扫立即购票
安全·方便·快捷

确定
CheckCode

主办单位

3
活动数
0
关注数

请先登录

免注册,使用合作网站登录

QQ 微信 微博